References
- Alvares C, Davies FE, Horton C, etal. Long-term outcomes of previously untreated myeloma patients: Responses to induc-tion chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005;129:607–614.
- Singhal S, Powles R, Sirohi B, et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002;30(10):673–679.
- Powles R, Sirohi B, Kulkarni S, et al. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: The first step towards an "operational cure"? Bone Marrow Transplant 2002;30:479–484.
- Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992;80:1818–1824.
- Corradini P, Voena C, Omede P, et al. Detection of circulating tumour cells in multiple myeloma by a PCR-based method. Leukemia 1993;7:1879–1882.
- Mariette X, Fermand JP, Brouet JC. Myeloma cell contami-nation of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994;14:47–50.
- Gazitt Y, Tian E, Barlogie B, et al. Differential mobilisation of myeloma cells and normal hematopoeitic stem cells in multiple myeloma after treatment with cyclophosphamide and gra-nulocyte-macrophage colony stimulating factor. Blood 1996;87:805–811.
- Levy Y, Schmitt C, Tsapis A, Brouet JC, Fermand JC. Phenotype and immunoglobulin gene configuration of B blood cells from patients with multiple myeloma. Clin Exper Immunol 1991;84:435–439.
- Witzig TB, Dhodapkar MV, Kyle RA, Greipp PR. Quanti-tation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993;72:108–113.
- Knudsen LM, Rasmussen T, Nikolaisen K, Johnsen HE. Mobilisation of tumour cells along with CD34 + cells to peripheral blood in multiple myeloma. Eur J Haematol Nov—Dec 2001;67(5-6):289–295.
- Boccadoro M, Omedé P, Dominietto A, et al. Multiple myeloma: The number of reinfused plasma cell does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant 2000;25:25–29.
- Lemoli RM, Martinelli G, Zamagni E, et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34 + cells to support single or tandem high-dose chemotherapy. Blood 2000;95:2234–2239.